^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

EGFR G719A

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
Phase 2
Shanghai Chest Hospital
Recruiting
Last update posted :
06/28/2022
Initiation :
12/08/2020
Primary completion :
10/31/2022
Completion :
12/01/2022
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719A • EGFR exon 18 mutation • EGFR L747P • EGFR T854A • EGFR D761Y • EGFR L861R • EGFR E709Q • EGFR E746 • EGFR I744_K745insKIPVAI • EGFR L747S • EGFR R776H • EGFR G779C • EGFR R776C
|
Vizimpro (dacomitinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2/3
The First Affiliated Hospital of Henan Universi...
Not yet recruiting
Last update posted :
01/26/2022
Initiation :
03/01/2022
Primary completion :
01/01/2024
Completion :
01/01/2025
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719A • EGFR G719S • EGFR G719C
|
carboplatin • pemetrexed • Ivesa (furmonertinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Fondazione Ricerca Traslazionale
Recruiting
Last update posted :
05/07/2021
Initiation :
06/12/2020
Primary completion :
12/31/2023
Completion :
12/31/2023
EGFR • HER-2 • BRAF • ALK • MET • ROS1
|
EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement • EGFR L861Q • ALK mutation • ROS1 rearrangement • MET mutation • EGFR S768I • EGFR G719A • EGFR G719S • EGFR G719C
|
Tagrisso (osimertinib) • Vizimpro (dacomitinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 3
National Cancer Institute, Naples
Active, not recruiting
Last update posted :
03/05/2021
Initiation :
04/01/2016
Primary completion :
12/01/2021
Completion :
07/01/2022
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR S768I • EGFR G719A • EGFR G719S • EGFR G719C
|
Avastin (bevacizumab) • erlotinib • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
SCRI Development Innovations, LLC
Completed
Last update posted :
03/06/2019
Initiation :
03/01/2014
Primary completion :
05/31/2016
Completion :
12/11/2017
EGFR
|
EGFR mutation • EGFR exon 19 deletion • EGFR L861Q • EGFR G719A • EGFR G719S • EGFR G719C
|
erlotinib • buparlisib (AN2025)
Phase N/A
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
05/21/2018
Initiation :
05/14/2015
Primary completion :
12/11/2017
Completion :
12/11/2017
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR S768I • EGFR G719A • EGFR exon 19 deletion + EGFR L861Q • EGFR exon 19 insertion
|
erlotinib • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Wenzhou Medical University
Unknown status
Last update posted :
11/01/2016
Initiation :
05/01/2016
Primary completion :
12/01/2017
Completion :
06/01/2018
EGFR
|
EGFR mutation • EGFR L858R • EGFR L861Q • EGFR G719A • EGFR G719S • EGFR G719C • EGFR exon 19 insertion
|
gefitinib • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)